Breakthrough T1D has reportedly dismissed three board members from its venture-capital arm, the T1D Fund, in a move the nonprofit states was necessary to safeguard donor interests. However, the ousted members allege that Breakthrough T1D has instead undermined the fund’s autonomy, sparking a significant internal conflict over the direction and independence of its investment strategies. This clash raises critical questions about the governance of nonprofit venture funds and the potential for mission creep or donor influence to impact independent investment decisions aimed at advancing research and treatments for Type 1 diabetes.
Adapted from: WSJ.com: Markets
